Eyenovia Inc (NASDAQ: EYEN) reported Q1 EPS of ($0.45), $0.07 worse than the analyst estimate of ($0.38).

1Q 2018 Business Highlights

• Raised $24.5 million in net proceeds from initial public offering in January 2018;
• Completed EYN PG21 study demonstrating a robust intraocular pressure (IOP) lowering effect of the company’s micro-therapeutic Latanoprost. Full results will be submitted for presentation at an upcoming medical conference;
• Received positive feedback from FDA to advance MicroProst for Chronic Angle Closure Glaucoma (CACG) into Phase III development;
• Received positive feedback from FDA to advance MicroPine for progressive pediatric Myopia into Phase III development with possibility of only one trial required for registration;
• Expanded executive management, Board of Directors and Scientific Advisory Board.

For earnings history and earnings-related data on Eyenovia Inc (EYEN) click here.